Literature DB >> 11190023

Frequency doubling perimetry and the detection of eye disease in the community.

G A Cioffi1, S Mansberger, P Spry, C Johnson, E M Van Buskirk.   

Abstract

PURPOSE: Frequency Doubling Technology (FDT) perimetry is a novel perimetric test that provides rapid screening (45 to 60 seconds) and full-threshold (4 to 5 minutes) testing for detection of vision loss. The purpose of this study was to determine the specificity and sensitivity of FDT perimetry for the detection of ocular disease.
METHODS: A total of 130 participants (257 eyes of 42 men and 88 women) recruited from the community completed FDT perimetry, standard achromatic automated perimetry (SAP), anterior segment biomicroscopy, tonometry, and dilated ophthalmoscopy. FDT results were considered abnormal if 1 point was abnormal (depressed below the 5% level on the screening protocol C-20-5). SAP was considered abnormal if the glaucoma hemifield test or pattern standard deviation was outside normal limits (P < .05) or a hemifield cluster of 3 depressed points on the pattern deviation probability plot (P < .05) was present. An abnormal eye examination was defined as the presence of an abnormality in the anterior segment, lens, or posterior segment that was likely to cause a visual field defect or the presence of glaucomatous or other optic neuropathy.
RESULTS: The mean age (+/- SD) of participants was 55.5 years (+/- 10.3). Ethnic groups, as reported by participants, included 77 (59%) African Americans, 40 (31%) Caucasians, and 13 (10%) in other groups. On clinical examination, 116 eyes (45%) were normal, 9 eyes (3.5%) had a cataract with best corrected visual acuity worse than 20/30, 16 eyes (6%) had open-angle glaucoma, and 17 eyes (7%) had retinal findings or lesions that were likely to cause a visual field defect. For FDT perimetry, 22 (8.6%) of 257 tests were unreliable, and for SAP, 65 (25.3%) of 257 tests were unreliable. The sensitivity and specificity of FDT perimetry for detecting an abnormal clinical examination were 55% and 90% and for detecting an abnormal examination that included an abnormal SAP, 64% and 86%.
CONCLUSIONS: FDP demonstrated reasonable discriminatory power for detecting eye disease.

Entities:  

Mesh:

Year:  2000        PMID: 11190023      PMCID: PMC1298226     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  17 in total

1.  Frequency doubling technology perimetry for detection of glaucomatous visual field loss.

Authors:  K E Cello; J M Nelson-Quigg; C A Johnson
Journal:  Am J Ophthalmol       Date:  2000-03       Impact factor: 5.258

2.  Screening for glaucomatous visual field loss with frequency-doubling perimetry.

Authors:  C A Johnson; S J Samuels
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-02       Impact factor: 4.799

3.  Automated suprathreshold screening for glaucoma: the Baltimore Eye Survey.

Authors:  J Katz; J M Tielsch; H A Quigley; J Javitt; K Witt; A Sommer
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-11       Impact factor: 4.799

4.  Screening for sight threatening eye disease. Calculation of sensitivity is misleading.

Authors:  M Hickey-Dwyer; S Ellerby
Journal:  BMJ       Date:  1996-02-17

5.  Screening for sight threatening eye disease. Cost effectiveness of screening modalities must be determined.

Authors:  P Adab
Journal:  BMJ       Date:  1996-02-17

6.  Screening for sight threatening eye disease. Stereoscopic viewing of the retina needed to identify maculopathy.

Authors:  R H Grey; J C Hart
Journal:  BMJ       Date:  1996-02-17

7.  Screening for glaucoma with frequency-doubling technology and Damato campimetry.

Authors:  N Yamada; P P Chen; R P Mills; M M Leen; M F Lieberman; R L Stamper; D C Stanford
Journal:  Arch Ophthalmol       Date:  1999-11

8.  Frequency doubling technology perimetry using a 24--2 stimulus presentation pattern.

Authors:  C A Johnson; G A Cioffi; E M Van Buskirk
Journal:  Optom Vis Sci       Date:  1999-08       Impact factor: 1.973

9.  Frequency doubling technique in patients with ocular hypertension and glaucoma: correlation with octopus perimeter indices.

Authors:  M Iester; A Mermoud; C Schnyder
Journal:  Ophthalmology       Date:  2000-02       Impact factor: 12.079

10.  Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study.

Authors:  S P Harding; D M Broadbent; C Neoh; M C White; J Vora
Journal:  BMJ       Date:  1995-10-28
View more
  7 in total

1.  Reliability of the first eye and second eye in frequency doubling technology perimetry.

Authors:  Satoshi Mukai; Hidetoshi Tsukamoto; Aiko Iwase; Hiromu K Mishima
Journal:  Jpn J Ophthalmol       Date:  2005 Sep-Oct       Impact factor: 2.447

2.  Performance of the 24-2-5 frequency doubling technology screening test: a prospective case study.

Authors:  P G D Spry; H M Hussin; J M Sparrow
Journal:  Br J Ophthalmol       Date:  2007-03-27       Impact factor: 4.638

3.  Predictive value of screening tests for visually significant eye disease.

Authors:  Laura J Kopplin; Steven L Mansberger
Journal:  Am J Ophthalmol       Date:  2015-06-04       Impact factor: 5.258

4.  Clinical evaluation of frequency doubling technology perimetry using the Humphrey Matrix 24-2 threshold strategy.

Authors:  P G D Spry; H M Hussin; J M Sparrow
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

5.  Portable Perimetry Using Eye-Tracking on a Tablet Computer-A Feasibility Assessment.

Authors:  Pete R Jones; Nicholas D Smith; Wei Bi; David P Crabb
Journal:  Transl Vis Sci Technol       Date:  2019-02-05       Impact factor: 3.283

6.  Comparison of visual field test results obtained through Humphrey matrix frequency doubling technology perimetry versus standard automated perimetry in healthy children.

Authors:  Sibel Kocabeyoglu; Salih Uzun; Mehmet Cem Mocan; Banu Bozkurt; Murat Irkec; Mehmet Orhan
Journal:  Indian J Ophthalmol       Date:  2013-10       Impact factor: 1.848

7.  Role of advanced technology in the detection of sight-threatening eye disease in a UK community setting.

Authors:  Bruno R Fidalgo; Priya Dabasia; Anish Jindal; David F Edgar; Irene Ctori; Tunde Peto; John G Lawrenson
Journal:  BMJ Open Ophthalmol       Date:  2019-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.